Opthea To Present at September Investor Conferences

Rhea-AI Summary

Opthea Limited (ASX:OPT) announced that CEO Dr. Megan Baldwin will participate in three investor conferences in September 2021. These events include Citi's 16th Annual BioPharma Virtual Conference on September 9, H.C. Wainwright Annual Healthcare Conference on September 13, and Oppenheimer Healthcare Fall Summit on September 20. Opthea is focused on developing therapies for retinal diseases, particularly its lead product candidate, OPT-302, currently in Phase 3 trials. The firm emphasizes the speculative nature of biotech investments due to various inherent risks.

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the following investor conferences in September:

Citi’s 16^th Annual BioPharma Virtual Conference
Date: Thursday, September 9, 2021 8:50 am ET (11:50 pm AEST)
Panel: Eyes on the Prize – Next Generation Retinal Therapeutics

H.C. Wainwright Annual Healthcare Conference
Date: Monday, September 13, 2021 7:00 am ET (9:00 pm AEST)

Oppenheimer Healthcare Fall Summit
Date: Monday, September 20, 2021 4:35 pm ET (Tuesday, September 21, 2021, 7:35 am AEST)
The presentations may be accessed on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

U.S.A. & International:	Australia:
Sam Martin	Rudi Michelson
Argot Partners	Monsoon Communications
Tel: +1 212-600-1902	Tel: +61 (0) 3 9620 3333
opthea@argotpartners.com

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com 

FAQ

When will Dr. Megan Baldwin represent Opthea Limited at investor conferences?

Dr. Megan Baldwin will present at Citi's BioPharma Conference on September 9, 2021, H.C. Wainwright Conference on September 13, and Oppenheimer Healthcare Summit on September 20, 2021.

What is the focus of Opthea Limited in its clinical trials?

Opthea Limited is focusing on developing new therapies for retinal diseases, particularly wet AMD and diabetic macular edema, with its lead product candidate OPT-302 in Phase 3 trials.

What is the significance of OPT-302 for retinal disease treatment?

OPT-302 aims to enhance treatment efficacy for retinal diseases by providing broader inhibition of the VEGF family when used in combination with anti-VEGF-A therapies.

Where can investors access the presentations from Opthea Limited's conferences?

Investors can access the presentations on Opthea's Investors page at www.opthea.com/presentations.

What risks should investors consider when investing in Opthea Limited?

Investors should consider the inherent risks associated with biotech investments, including the lengthy clinical trial process and the uncertainty of regulatory approvals.